Covirabio GmbH is a young Start-Up company with the vision to enable pathogen detection and immune monitoring at the Point-of-Care or Point-of-Need. Based on the Covirabio technology platform VERB (Virus Entry Receptor Binding), a portfolio of test systems for the detection of SARS-CoV-2 infections or the immune response to an infection and/or vaccination is currently being developed. For the use at the Point-of-Care or Point-of-Need, the assays are integrated into microfluidic systems. This technology platform is now also expanded to bacterial pathogens.